|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
99-100
|
|
pubmed:dateCreated |
2010-8-11
|
|
pubmed:abstractText |
Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis. We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0172-6390
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
562-6
|
|
pubmed:meshHeading |
pubmed-meshheading:20698227-Adult,
pubmed-meshheading:20698227-Aged,
pubmed-meshheading:20698227-Anemia, Hemolytic,
pubmed-meshheading:20698227-Angiopoietin-2,
pubmed-meshheading:20698227-Antiviral Agents,
pubmed-meshheading:20698227-Female,
pubmed-meshheading:20698227-Haptoglobins,
pubmed-meshheading:20698227-Hepatitis C, Chronic,
pubmed-meshheading:20698227-Humans,
pubmed-meshheading:20698227-Male,
pubmed-meshheading:20698227-Middle Aged,
pubmed-meshheading:20698227-Neovascularization, Physiologic,
pubmed-meshheading:20698227-Ribavirin,
pubmed-meshheading:20698227-Vascular Endothelial Growth Factor A
|
|
pubmed:articleTitle |
Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?
|
|
pubmed:affiliation |
University of Cumhuriyet, Department of Gastroenterology, Sivas, Turkey. ozlemyonem@gmail.com
|
|
pubmed:publicationType |
Journal Article
|
